STRASBOURG, France, April 16 /CNW/ - Transgene S.A. (Eurolist Paris:
FR0005175080) announces its cash position and net cash expenditures for the
three months ending March 31, 2007 (unaudited figures, IAS/IFRS).
Cash, cash equivalents and short term investments totaled EUR
13.9 million at March 31, 2007.
For the first three months of 2007, net cash expenditures amounted to
EUR 6.7 million compared to EUR 5.3 million for the first three months of
2006. The increase is mainly due to a reduction of the cash received for third
party manufacturing while expenses remained stable. This evolution is in line
with the net cash expenditure projections of EUR 25 million made by the
management for 2007. However, these projections do not take into account cash
to be received from Roche under our recently announced product development
partnership (see our press release dated April 11, 2007).
Transgene is a France-based biopharmaceutical company dedicated to the
development of therapeutic vaccines and immunotherapeutic products in oncology
and infectious diseases. The company has three compounds in Phase II trials
and one compound in Phase I studies. Transgene has bio-manufacturing
production capacities for viral-based vectors and technologies available for
out-licensing. For further information about Transgene, please visit
For further information:
For further information: Transgene, Philippe Poncet, +-33-3-88-27-91-21;
Capital MS&L, Mary Clark, Halina Kukula, +44-(0)20-7307-5330; Image 7, Estelle
Guillot-Tantay, Tiphaine Hecketsweiler, +33-1-53-70-74-93